Ademetionine 1,4-Butanedisulfonate

Phase 2Small molecule

CChina National Center for Cardiovascular Diseases

Ademetionine 1,4-Butanedisulfonate is one of 54 small molecule programs targeting Hyperbilirubinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaActive, not recruiting

Hypertrophic CardiomyopathyActive, not recruiting

HyperbilirubinemiaPreclinical

Active, not recruiting

Hypertrophic CardiomyopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Hypertrophic Cardiomyopathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Zebeta

Teva

Approved

1 3

Adenocard

Astellas

Approved

1 4

Lexiscan

Astellas

Approved

1 5

Bayer Aspirin

Bayer

Approved

—6

Cardizem

BBausch Health Americas, Inc.

Approved

2 7

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

19 8

Calan

VVal Adams

Approved

1 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Xarelto

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ARecruiting

Hyperbilirubinemia

NCT06922669

Q4 2027

Phase 2Recruiting

Hypertrophic Cardiomyopathy

NCT07367724

Clinical

Trials by Indication[1]

Hyperbilirubinemia1 trial

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06922669·232 enrolled

Hypertrophic Cardiomyopathy1 trial

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 2·NCT07367724·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ademetionine 1,4-Butanedisulfonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ademetionine 1,4-Butanedisulfonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ademetionine 1,4-Butanedisulfonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — China National Center for Cardiovascular Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChina National Center for Cardiovascular Diseases

Ademetionine 1,4-Butanedisulfonate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Hyperbilirubinemia1 trial

Hypertrophic Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News